Answers are grounded in this paper and cite their sources.
Novel small-molecule agents improve antitumor responses in cancers with varying PD-L1 levels, suggesting better personalized treatments.
Immune checkpoint blockade targeting PD-1/PD-L1 has transformed cancer treatment but faces challenges such as low response rates and a lack of reliable biomarkers. To address these issues, we developed a novel small-molecule immunotheranostic agent, [¹⁸F]LG-8, and its therapeutic counterpart LG-8, which share identical structures to ensure consistent biodistribution. [¹⁸F]LG-8 PET specifically quantified PD-L1 in murine melanoma (B16-F10) and lung carcinoma (LLC) models. LG-8 exhibited potent antitumor efficacy in B16-F10 tumors with high PD-L1 uptake but not in LLC models with low PD-L1 expression, confirming the predictive value of the diagnostic scan. Furthermore, we implemented an individualized chemo-immunotherapy strategy guided by [¹⁸F]LG-8 PET imaging, where cisplatin pretreatment enhanced PD-L1 expression in a subset of LLC tumors, enabling effective LG-8 treatment only in mice with elevated PD-L1 levels. This theranostic approach integrates precise diagnosis and immunotherapy within a unified molecular platform, significantly improving response prediction and advancing personalized cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: